Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Immunotherapy in breast cancer treatment

View through CrossRef
Breast cancer is one of the most common types of cancer affecting women worldwide. In recent years, immunotherapy has emerged as a promising treatment option for breast cancer. Immunotherapy refers to the use of treatments that enhance the body's natural immune response to fight cancer. This type of therapy has shown promising results in patients with breast cancer, offering the potential for improved outcomes and quality of life. There are several types of immunotherapies used in the treatment of breast cancer, including immune checkpoint inhibitors, cancer vaccines, adoptive cellular therapy, oncolytic virus therapy, and immunomodulators. These treatments work by targeting specific components of the immune system to enhance the immune response against cancer cells. Although immunotherapy holds promise for the treatment of breast cancer, there are a number of drawbacks. Currently, only a subset of patients with breast cancer are eligible for immunotherapy, and not all patients with breast cancer will respond to these treatments. Additionally, immunotherapy can cause immune-related side effects, and can be expensive, limiting access for some patients. In spite of these limitations, the field of immunotherapy for breast cancer is rapidly evolving, with ongoing research aimed at improving the effectiveness and safety of these treatments. The future of immunotherapy in the treatment of breast cancer is promising, with a focus on personalized immunotherapy, combination therapies, biomarker discovery, immune monitoring, and the development of new immunotherapies. Overall, immunotherapy offers a promising treatment option for patients with breast cancer. Through continued research and innovation, it is hoped that immunotherapy will become a standard treatment option, offering improved outcomes and quality of life for patients with breast cancer.
The Applied Biology & Chemistry Journal
Title: Immunotherapy in breast cancer treatment
Description:
Breast cancer is one of the most common types of cancer affecting women worldwide.
In recent years, immunotherapy has emerged as a promising treatment option for breast cancer.
Immunotherapy refers to the use of treatments that enhance the body's natural immune response to fight cancer.
This type of therapy has shown promising results in patients with breast cancer, offering the potential for improved outcomes and quality of life.
There are several types of immunotherapies used in the treatment of breast cancer, including immune checkpoint inhibitors, cancer vaccines, adoptive cellular therapy, oncolytic virus therapy, and immunomodulators.
These treatments work by targeting specific components of the immune system to enhance the immune response against cancer cells.
Although immunotherapy holds promise for the treatment of breast cancer, there are a number of drawbacks.
Currently, only a subset of patients with breast cancer are eligible for immunotherapy, and not all patients with breast cancer will respond to these treatments.
Additionally, immunotherapy can cause immune-related side effects, and can be expensive, limiting access for some patients.
In spite of these limitations, the field of immunotherapy for breast cancer is rapidly evolving, with ongoing research aimed at improving the effectiveness and safety of these treatments.
The future of immunotherapy in the treatment of breast cancer is promising, with a focus on personalized immunotherapy, combination therapies, biomarker discovery, immune monitoring, and the development of new immunotherapies.
Overall, immunotherapy offers a promising treatment option for patients with breast cancer.
Through continued research and innovation, it is hoped that immunotherapy will become a standard treatment option, offering improved outcomes and quality of life for patients with breast cancer.

Related Results

Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
PO-285 A review of effects of exercise on the quality of life in breast cancer survivors
PO-285 A review of effects of exercise on the quality of life in breast cancer survivors
Objective Breast cancer is one of the most common malignant tumors in women.The number of women diagnosed with breast cancer each year is also increasing.It is also the leading cau...
Effect of type lll collagen coating of electrospun scaffolds on breast cancer cell apoptosis
Effect of type lll collagen coating of electrospun scaffolds on breast cancer cell apoptosis
Breast cancer arises from the epithelial or the connective tissue components of the breast. Breast cancer is the most commonly diagnosed cancer in women, with about half a million ...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Abstract P3-09-11: A genetically underserved community
Abstract P3-09-11: A genetically underserved community
Abstract It is estimated 5-10% of breast cancer can be attributed to a hereditary predisposition. By knowing a woman's risk for breast cancer, risk reduction strateg...

Back to Top